Annual report [Section 13 and 15(d), not S-K Item 405]

Revenues from Contracts and Significant Customers (Tables)

v3.26.1
Revenues from Contracts and Significant Customers (Tables)
12 Months Ended
Dec. 31, 2025
Revenues from Contracts and Significant Customers  
Schedule of disaggregation of total revenues

Year Ended December 31, 

($ in thousands)

  ​ ​ ​

2025

  ​ ​ ​

2024

Emrosi

$

14,745

$

Qbrexza

25,014

25,114

Accutane

12,882

19,407

Foam franchise products (Amzeeq & Zilxi)

5,859

6,652

Other / legacy product revenue

2,739

3,961

Collaboration revenue

1,500

Revenue – related party

 

 

41

Other revenue

2,023

 

1,000

Total net revenue

$

63,262

$

57,675